Yahoo Greenie So happy for you!! Blessing Jeanie Sent from my iPhone
> On Nov 11, 2014, at 4:05 PM, Myvety2k via CMLHope <cmlhope@googlegroups.com> > wrote: > > I received my results back from my 6 month blood work today and I'm Negative > on BCR-ABL. > > greenie > > In a message dated 11/11/2014 2:14:49 P.M. Eastern Standard Time, > cmlhope@googlegroups.com writes: > Happy Veterans Day to all > JeanieđČđșđžđșđž > > Sent from my iPhone > >> On Nov 11, 2014, at 1:56 PM, Myvety2k via CMLHope <cmlhope@googlegroups.com> >> wrote: >> >> Thank you Elizabeth, I served 6 years in the Navy. >> >> greenie >> >> In a message dated 11/11/2014 1:43:34 P.M. Eastern Standard Time, >> ksnwo...@prodigy.net writes: >> Thinking of you all. Nick is critically anemic due to Gleevec. Hope >> Richard H., Shannon, Bobbie Doyle, and all keep up your sharing of info. >> thanks so much Marty for the reports from the clinical trials to reduce or >> stop Gleevec. >> Thank you to all Veterans on this day. Elizabeth Woods >> >> >> On Tuesday, November 11, 2014 4:32 AM, "cmlhope@googlegroups.com" >> <cmlhope@googlegroups.com> wrote: >> >> >> cmlhope@googlegroups.com Google Groups >> Topic digest >> View all topics >> Glivec and studies of stopping the drug - 1 Update >> Digest for cmlhope@googlegroups.com - 6 updates in 2 topics - 1 Update >> Glivec and studies of stopping the drug >> Richard H <rbhuffm...@gmail.com>: Nov 10 09:05PM -0800 >> >> Yes. This was the reason I stopped Gleevec. I was also had Iron Deficient >> Anemia. I had to infuse the iron to help try to recover my RBC >> count >> because was below 9. I was also still taking Gleevec while doing this. >> On Monday, November 10, 2014 12:56:18 AM UTC-6, Shannon L wrote: >> Back to top >> Digest for cmlhope@googlegroups.com - 6 updates in 2 topics >> "Sue" <hol...@iinet.net.au>: Nov 10 07:13PM +0800 >> >> Hi Shannon >> >> >> >> There is also the Destiny Trial in the UK which is reduction down to 200mg >> for 12 months and then stop (there has been no report until after Dec 2014) >> >> The next Trial is named Spirit3 to see if people are being over medicated >> >> >> >> The Australian Survey will have 600 participants >> >> >> >> Sue Hurt >> >> (Australian) >> >> >> >> From: cmlhope@googlegroups.com [mailto:cmlhope@googlegroups.com] >> Sent: Monday, 10 November 2014 6:22 PM >> To: Digest recipients >> Subject: [CMLHope] Digest for cmlhope@googlegroups.com - 6 updates in 2 >> topics >> >> >> >> >> cmlhope@googlegroups.com >> >> <https://groups.google.com/forum/?utm_source=digest&utm_medium=email/#!overview> >> Google Groups >> >> <https://groups.google.com/forum/?utm_source=digest&utm_medium=email/#!overview> >> >> >> Topic digest >> View all topics >> >> * Glivec and studies of stopping the drug - 5 Updates >> >> * Glivec and studies of stopping the drug - 1 Update >> >> <http://groups.google.com/group/cmlhope/t/839da881a2e6e455?utm_source=digest&utm_medium=email> >> Glivec and studies of stopping the drug >> >> >> Shannon L <shannonl.cam...@gmail.com <mailto:shannonl.cam...@gmail.com> >: >> Nov 09 03:58AM -0800 >> >> Hi All My name is Shannon I live in Sydney Australia >> Its been awhile since I have posted. >> I was diagnosed 1998 and after a few years went onto sti571 (glivec) and >> achieved remission within 2 months and I have been it ever since about 14 >> yrs. >> They are inviting participants (in Australia) to take a survey of stopping >> glivec I image they will do a study of stopping the drug. >> My question is does everyone know of the study done in USA of the stats of >> stopping they have indicated in this survey info that the percentage of >> success is 30-40% to me that SEEMS LOW what do you think. >> I do have some problems but I am stable on glivec. >> I hope this emil finds everyone well >> Shannon >> >> >> Marty Gartenberg <wa2...@gmail.com <mailto:wa2...@gmail.com> >: Nov 09 >> 07:46AM -0500 >> >> Hi Shannon, there is a study called the STIM that is going on in the UK and >> it talks about Imatinib being stopped. It is kind of lengthily however it >> does go into detail. >> Good luck to you, and I have always said there will be a cure >> for CML in >> our lifetimes. >> If you follow any of my posts I always end them with two numbers. They are >> 18 which is the symbol for life. >> 18's to you Shannon >> Marty >> PS Shannon I encourage you to post any time that you like. There will >> usually be someone that may be able to answer your questions. Besides that >> we are all here to learn from and help each other >> Can Imatinib Be Stopped? >> >> Goodwin, Peter >> Article Outline >> [image: Collapse Box]Author Information >> >> ASH Abstracts 186 and 187 >> >> SAN FRANCISCOâThe early promise of the tyrosine kinase inhibitor (TKI) >> imatinib for treating chronic myeloid leukemia (CML) has continued to be >> fulfilled following the release of seven-year follow-up data at the ASH >> Annual Meeting here from the International Randomized Study of Interferon >> versus STI 571 (imatinib) (IRIS) with 553 patients. >> >> With diminishing rates of progression each year beyond year three, the case >> for stopping imatinib altogether was also discussed at the meeting >> following release of results from two studies in which the drug was >> discontinued among patients who had achieved enduring complete molecular >> responses to it for more than two years. >> >> IRIS investigator Stephen G. O'Brien MD, PhD, Senior Lecturer in >> Experimental Hematology at Northern Institute for Cancer Research of >> University of Newcastle upon Tyne, UK, gave the latest IRIS results to a >> packed audience at the meeting, showing an event-free survival rate of 81%, >> freedom from progression to accelerated phase/blast crisis of 93%, and an >> estimated overall survival rate of 86%, from the standard dose >> of 400 mg >> imatinib daily. >> >> And in the presentation that followed, François-Xavier Mahon, MD, Professor >> at Victor SĂ©galen University in Bordeaux, France, released early data from >> the Stop Imatinib (STIM) study, noting that remissions continued in about >> half of the patients after investigational discontinuation of imatinib >> therapyâwith a non-significant trend showing that patients previously >> treated with interferon were more likely to be among those whose remissions >> persisted without drugs. >> >> Dr. O'Brien said that in IRIS the projected cytogenetic response rate to >> imatinib (by Kaplan Meyer analysis) was 82%, and that after seven years of >> follow-up 60% of patients were still on imatinib, with 57% of all patients >> still in complete cytogenetic response (CCR). >> >> The impression that CCR holds the key to a âcureâ of CML was strengthened >> by comments he made after his talk: >> >> âIt seems that if you maintain your CCR for, say, three years, the chance >> of regressing at that point is essentially zero. So, achieving a CCR is, I >> guess, what we call a âsafe havenâ for the majority of patients: If you've >> achieved that and sustained it for, say, three years, you're in pretty good >> shape and the chance of progressing is virtually nil,â he said. >> Back to Top >> <http://journals.lww.com/oncology-times/Fulltext/2009/02101/Can_Imatinib_Be_Stopped_.1.aspx# >> >> <http://journals.lww.com/oncology-times/Fulltext/2009/02101/Can_Imatinib_Be_Stopped_.1.aspx> >> > >> | Article Outline >> Diminishing Rates of Relapse >> >> These words reflect the diminishing rates of relapse observed in the IRIS >> study in successive years. Rates of progression to accelerate phase or >> blast crisis each year were low at all timesâwith rates rising in the first >> two years (1.5% in the first year; 2.8% in the second year) and then >> diminishing after that (1.6%, 0.9%, 0.5%, 0%, 0.4% in years 3, 4, 5, 6, and >> 7, respectively)âwith only a single patient having disease progression to >> accelerate phase or blast crisis between years six and seven. >> [image: Figure. FRANOIS-XAVI...] >> Figure. FRANOIS-XAVI... >> Image Tools >> >> The total annual event rates, including loss of molecular complete >> remission and death, were similarly low (3.3% and 7.5%) in years one and >> two, and diminished thereafter (4.8%, 1.7%, 0.8%, 0.3%, and 2.0% in years >> three through seven). >> >> These data only apply, of course, to the majority of patients who prove >> sensitive to imatinib, and Dr. O'Brien noted that many patients who >> are >> resistant or refractory to the TKI are now candidates for other drugs and >> in some cases, allogeneic transplantation. >> >> Dr. O'Brien summed up his feelings about the current state of the art >> concerning imatinib therapy for CML: âI think it's encouraging on two >> fronts. One is that there's nothing new in years six and seven to cause >> alarm in terms of safety events. And the second isâparticularly in patients >> who achieved a complete cytogenetic responseâI think we can be very >> reassured that the vast majorityâespecially if you have that CCR for three >> yearsâare doing extremely well, with very few of those progressing.â >> Back to Top >> <http://journals.lww.com/oncology-times/Fulltext/2009/02101/Can_Imatinib_Be_Stopped_.1.aspx# >> >> <http://journals.lww.com/oncology-times/Fulltext/2009/02101/Can_Imatinib_Be_Stopped_.1.aspx> >> > >> | Article Outline >> STIM Study >> >> Encouraging data on long-term remission of CML among patients treated with >> imatinib gave rise to the French initiative to conduct a pilot study with >> 15 patients looking at stopping imatinib, and following this the >> multicenter STIM study with 50 patients, which began in July 2007 but which >> has already yielded earlyâbut provocativeâevidence that remission from CML >> can continue even after imatinib is stopped. >> >> Dr. Mahon said that patients were recruited into these studies only if they >> had received imatinib for at least three years and achieved sustained >> complete molecular remission (CMR) for two years before experimentally >> stopping the drug. >> >> The definition of sustained CMR was strict: BCR-ABL/ABL had to be below a >> detection threshold corresponding to a 5-log reduction (undetectable signal >> using RQ-PCR) for at least two years. Molecular relapse was defined as >> RQ-PCR positivity detected in two successive assays, and patients who >> relapsed were then retreated with imatinib (successfully) at a dose of 400 >> mg daily. >> >> In the latest follow-up of the pilot study, Dr. Mahon said that seven out >> of 15 patients had relapse within six months and all were restored to CMR >> by re-treatment with imatinib. The remaining eight patients were still in >> CMR a median of 37 months after stopping the drug. >> >> All of the patients in the pilot study had been treated with interferon >> before receiving imatinib, most of them responding to it. This raised the >> suggestionâwhich Dr. Mahon discussed in his talk at the ASH meetingâthat >> interferon may have conferred a benefit among patients who were >> subsequently treated with imatinib. >> >> Half of the patients in the STIM study had been pretreated with interferon, >> and some provocativeâbut as yet not statistically significantâdata have >> emerged showing an advantage among those who had previously received >> interferon before going on to imatinib therapy. >> >> By July 2008, 10 of the 15 patients who were still in CMR had received >> prior interferon. The latest assessment from a slide Dr. Mahon presented >> showed that 27 out of 49 patients followed for more than six months had had >> disease relapse; 14 of these had received only imatinib and the remaining >> 13 had been previously treated with interferon, while only two of the seven >> patients in STIM who have so far continued in CMR for 14 months had been >> treated with imatinib alone. >> >> Dr. Mahon summed up his interim conclusions by stating that they have >> confirmed that CMR can be sustained after stopping imatinib, and that >> although there seems to be an [as yet statistically unconfirmed] advantage >> among the patients who received interferon, it is possible to stop the drug >> in patients with sustained CMR even among those treated with imatinib alone. >> >> He reported that the probability of survival without molecular relapse nine >> months after discontinuing imatinib was 46%, with the curve looking flat, >> so far, out to 15 months. Importantly, the STIM study found that all >> patients were sensitive after imatinib re-challenge. >> Back to Top >> <http://journals.lww.com/oncology-times/Fulltext/2009/02101/Can_Imatinib_Be_Stopped_.1.aspx# >> >> <http://journals.lww.com/oncology-times/Fulltext/2009/02101/Can_Imatinib_Be_Stopped_.1.aspx> >> > >> | Article Outline >> âRecurring Questionâ >> >> When Dr. O'Brien was asked for a comment on Dr. Mahon's conclusion from the >> initial pilot study and the early results from the STIM study, he said, >> âI'm fascinated by it. There's probably a bit of a cultural difference, I >> think, because most of my patients in the UKâwhen I suggest >> [stopping]âdon't want to hand their pills back, and want to carry on. >> [image: Figure. STEPHEN G. O...] >> Figure. STEPHEN G. O... >> Image Tools >> >> âI think that's driven by the fact that they are tolerating the drug well. >> There are no safety concerns emerging with the long-term follow-up. And >> it's obviously having good efficacy in them. But this is a recurring >> question that I think we'll see more and more ofâand the French study is >> very important.â >> Back to Top >> <http://journals.lww.com/oncology-times/Fulltext/2009/02101/Can_Imatinib_Be_Stopped_.1.aspx# >> >> <http://journals.lww.com/oncology-times/Fulltext/2009/02101/Can_Imatinib_Be_Stopped_.1.aspx> >> > >> | Article Outline >> Low Toxicities >> >> In the UK, he noted, the preference for continuing imatinib could be >> explained by relatively low toxicities, which were not a significant >> barrier to its use, with neutropenia and thrombocytopenia being minor >> toxicities that are merely irritating over time. >> >> âGI toxicity like diarrhea, for example, and a feeling of fatigue and >> malaise, sometimes, and muscle cramps can be troublesome in some patients >> over the years. But they're usually minor toxicities which, after many >> years, become rather wearing, rather than major toxicities,â he said. >> >> The bottom line for clinicians treating their patients with CML, according >> to Dr. O'Brien's interpretation of his IRIS results, is that imatinib at >> 400 mg remains the current standard for first-line drug therapy, even >> though there are exciting data among patient cohorts treated with nilotinib >> and dasatinib first-line, with cytogenetic response rates in excess of 95%. >> >> âI thinkâfor the futureâwhere we're going is to do comparative Phase III >> studies with the tyrosine kinase inhibitors in newly diagnosed patients to >> see if we can improve on imatinib. Because although the imatinib data is >> reassuring, it's clear that at six or seven years, perhaps a third of >> patients are not continuing on imatinib,â he said. >> >> *Supported by funding from Genentech BioOncology and Biogen Idec.* >> >> © 2009 Lippincott Williams & Wilkins, Inc. >> >> >> >> Shannon L <shannonl.cam...@gmail.com <mailto:shannonl.cam...@gmail.com> >: >> Nov 09 03:52PM -0800 >> >> Hi Everyone >> Thankyou Marty for the research information it was very informative, so >> they are combining stopping with interferon unfortunately I can't tolerate >> it I remember the first time before glivec. >> I hope everyone is having a wonderful day. >> >> On Sunday, November 9, 2014 10:58:55 PM UTC+11, Shannon L wrote: >> >> >> Richard H <rbhuffm...@gmail.com <mailto:rbhuffm...@gmail.com> >: Nov 09 >> 09:33PM -0800 >> >> What a great record. You didn't indicate how much Gleevec you are taking. >> I have read that several CMLers are taking reduced amounts and reaming in >> remission. I have seen a post by a lady that said see was very petite and >> she was only taking 100mg instead of 400mg. >> I don't know the percentage or of a combined results From the different >> studies I read sometime ago I believe the range you have is consistent with >> what I have read. You can read my results below. My ONC told be I needed >> to end my almost 6 year vacation and I am trying to requalify for a lower >> copay for Bosutinib. I have tested and they found no mutation. I have >> studied the side effects and I will be meeting with a Nurse to go over the >> side effects. Due to my other problems I am concerned about all the >> interactions with those Meds. >> I hope this has helped you. >> >> Richard H. >> >> Dxd 2/2003 >> >> 400mg Gleevec 3/2003 >> >> Undetectable 11/03 >> >> RT-PCR negative 11/04 >> >> QT-PCR .003 11/05 >> >> RBC 8. >> >> Gleevec Vacation 11/06-6/07 >> >> Iron infusion 11/06 >> >> Transfusions 12/06-5/07 >> >> QT-PCR .007 >> >> Gleevec 1/08 -5/08 >> >> Procrit 8/08-11/08 >> >> Gleevec Vacation 7/08-Present >> >> QT-PCR .003 4/09 >> >> QT-PCR .0015 6/09 >> >> QT-PCR .0021 9/09 >> >> QT-PCR .0028 1/10 >> >> QT-PCR .001 4/10 >> >> QT-PCR .00468 10/10 >> >> QT-PCR 1.049% 2/11 >> >> QT-PCR .0612% 8/11 >> >> QT-PCR 2.616 % 2/12 >> >> QT-PCR 2.410% 8/12 >> >> RT-PCR 9.183% 4/13 >> >> RT-PCR 4.57% 6/13 >> >> RT-PCR 10.183% 10/13 >> >> RT-PCR 10.577% 2/14 >> >> RT-PCR 16.050% 5/14 >> >> On Sunday, November 9, 2014 5:58:55 AM UTC-6, Shannon L wrote: >> >> >> >> Shannon L <shannonl.cam...@gmail.com <mailto:shannonl.cam...@gmail.com> >: >> Nov 09 10:56PM -0800 >> >> Hi Richard H >> >> Yes Glivec 400 mg has been good to me I have been very stable on the drug, >> Wow 6 years off glivec thank you so much for sharing your results just a >> question in your first holiday off glivec you had an iron injection is this >> because of cml? I am contemplating a small break as my stomach problems >> seem to be increasing and are at times very debilitating. I know I have >> been on many meds prior to glivec (chemo twice, cytarabine, hydroxia, and >> interferon) and Im sure my body sometimes struggles with it all. >> >> On Sunday, November 9, 2014 10:58:55 PM UTC+11, Shannon L wrote: >> >> Back to top >> >> <http://groups.google.com/group/cmlhope/t/22ca310a00448c54?utm_source=digest&utm_medium=email> >> Glivec and studies of stopping the drug >> >> >> myvet...@aol.com <mailto:myvet...@aol.com> : Nov 09 07:32AM -0500 >> Back to top >> You received this digest because you're subscribed to updates for this >> group. You can change your settings on the group membership page. >> To unsubscribe from this group and stop receiving emails from it send an >> email to cmlhope+unsubscr...@googlegroups.com. >> >> >> -- >> -- >> [CMLHope] >> A support group of http://cmlhope.com >> ------------------------------------------------- >> >> You received this message because you are subscribed to the Google Groups >> "CMLHope" group. >> To post to this group, send email to CMLHope@googlegroups.com >> To unsubscribe from this group, send email to >> cmlhope-unsubscr...@googlegroups.com >> For more options, visit this group at http://groups.google.com/group/CMLHope >> --- >> You received this message because you are subscribed to the Google Groups >> "CMLHope" group. >> To unsubscribe from this group and stop receiving emails from it, send an >> email to cmlhope+unsubscr...@googlegroups.com. >> For more options, visit https://groups.google.com/d/optout. >> -- >> -- >> [CMLHope] >> A support group of http://cmlhope.com >> ------------------------------------------------- >> >> You received this message because you are subscribed to the Google Groups >> "CMLHope" group. >> To post to this group, send email to CMLHope@googlegroups.com >> To unsubscribe from this group, send email to >> cmlhope-unsubscr...@googlegroups.com >> For more options, visit this group at http://groups.google.com/group/CMLHope >> --- >> You received this message because you are subscribed to the Google Groups >> "CMLHope" group. >> To unsubscribe from this group and stop receiving emails from it, send an >> email to cmlhope+unsubscr...@googlegroups.com. >> For more options, visit https://groups.google.com/d/optout. > -- > -- > [CMLHope] > A support group of http://cmlhope.com > ------------------------------------------------- > > You received this message because you are subscribed to the Google Groups > "CMLHope" group. > To post to this group, send email to CMLHope@googlegroups.com > To unsubscribe from this group, send email to > cmlhope-unsubscr...@googlegroups.com > For more options, visit this group at http://groups.google.com/group/CMLHope > --- > You received this message because you are subscribed to the Google Groups > "CMLHope" group. > To unsubscribe from this group and stop receiving emails from it, send an > email to cmlhope+unsubscr...@googlegroups.com. > For more options, visit https://groups.google.com/d/optout. > -- > -- > [CMLHope] > A support group of http://cmlhope.com > ------------------------------------------------- > > You received this message because you are subscribed to the Google Groups > "CMLHope" group. > To post to this group, send email to CMLHope@googlegroups.com > To unsubscribe from this group, send email to > cmlhope-unsubscr...@googlegroups.com > For more options, visit this group at http://groups.google.com/group/CMLHope > --- > You received this message because you are subscribed to the Google Groups > "CMLHope" group. > To unsubscribe from this group and stop receiving emails from it, send an > email to cmlhope+unsubscr...@googlegroups.com. > For more options, visit https://groups.google.com/d/optout. -- -- [CMLHope] A support group of http://cmlhope.com ------------------------------------------------- You received this message because you are subscribed to the Google Groups "CMLHope" group. To post to this group, send email to CMLHope@googlegroups.com To unsubscribe from this group, send email to cmlhope-unsubscr...@googlegroups.com For more options, visit this group at http://groups.google.com/group/CMLHope --- You received this message because you are subscribed to the Google Groups "CMLHope" group. To unsubscribe from this group and stop receiving emails from it, send an email to cmlhope+unsubscr...@googlegroups.com. For more options, visit https://groups.google.com/d/optout.
